Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rohto Pharmaceutical Co ( (JP:4527) ) has shared an announcement.
Rohto Pharmaceutical Co., Ltd. has revised its earnings and dividend forecasts for the fiscal year ending March 31, 2026, due to stronger-than-expected performance in Japan, Asia, and the Americas. The company anticipates higher net sales and profits, leading to an increased year-end dividend of 22 yen per share, up from the previous forecast, reflecting the company’s commitment to returning profits to shareholders.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2684.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of healthcare products, including over-the-counter medications, skincare, and cosmetics. The company primarily serves markets in Japan, Asia, and the Americas.
Average Trading Volume: 641,393
Technical Sentiment Signal: Sell
Current Market Cap: Yen560.7B
For an in-depth examination of 4527 stock, go to TipRanks’ Overview page.